Reimbursed Care Access in Saint Helena, Ascension and Tristan da Cunha

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; possession, supply or importation is subject to severe penalties. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; possession, supply or importation is subject to severe penalties. #.

Esketamine (Spravato) is a licensed nasal formulation in some jurisdictions for treatment‑resistant depression, but access and reimbursement vary widely and it is not routinely provided through UK public reimbursement pathways (NHS) in many regions; private access requires specialist clinics and specific risk‑mitigation measures. For UK services the nasal esketamine product is available in specialist centres but has not been approved for routine NHS commissioning in all areas and is typically provided via private payment or limited NHS pathways where approved #. Media coverage at the time of European approval noted licensing but implementation and routine public funding decisions are separate processes. #. Given the very small, remote health systems of Saint Helena, Ascension and Tristan da Cunha, there is no public evidence of local routine reimbursement or local specialist services providing esketamine; any access would therefore most likely be private, exceptional, or via overseas referral.

Ketamine is an established injectable anaesthetic and analgesic used worldwide and appears on the WHO Model List of Essential Medicines for anaesthesia, so it is routinely part of standard medical supply chains and used in acute care settings internationally. #.

In psychiatric practice, ketamine is commonly used off‑label (intravenous, intranasal formulations, or other routes) for rapid antidepressant effects in treatment‑resistant depression in specialist centres; such use is typically delivered by specialist clinics and is not universally reimbursed by public systems — it is often provided privately or within research/managed-access programs. In UK practice notes, esketamine (a ketamine derivative) has a licensed indication while racemic ketamine remains largely off‑label for depression and is delivered under local specialist protocols when used. #.

For Saint Helena, Ascension and Tristan da Cunha specifically, routine healthcare services are small and focus on primary and emergency care; while ketamine as an anaesthetic would be the most likely of these compounds to be present for surgical/acute use owing to its WHO essential‑medicine status, there is no evidence of established, locally reimbursed psychiatric ketamine programs or public funding for off‑label antidepressant ketamine—such treatments would likely require referral off‑island or private arrangements.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession or importation for non‑research purposes would risk criminal sanction. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; plant preparations containing DMT (ayahuasca) fall under the same controlled‑substance restrictions. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline preparations are therefore not legally available for medical use outside approved trials. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; substituted phenethylamines such as 2C‑series compounds are criminalised in most UK jurisdictions and related territories. #.